Compare OPAL & ASMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OPAL | ASMB |
|---|---|---|
| Founded | 1998 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Natural Gas Distribution | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 60.1M | 442.9M |
| IPO Year | 2021 | 2010 |
| Metric | OPAL | ASMB |
|---|---|---|
| Price | $2.17 | $28.19 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | $2.72 | ★ $44.20 |
| AVG Volume (30 Days) | ★ 183.5K | 112.0K |
| Earning Date | 05-11-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 650.00 | 91.78 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $348,975,000.00 | N/A |
| Revenue This Year | $12.84 | N/A |
| Revenue Next Year | $9.11 | $638.39 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 16.34 | N/A |
| 52 Week Low | $1.65 | $13.70 |
| 52 Week High | $4.08 | $39.71 |
| Indicator | OPAL | ASMB |
|---|---|---|
| Relative Strength Index (RSI) | 49.51 | 48.50 |
| Support Level | $2.02 | $26.50 |
| Resistance Level | $2.44 | $31.11 |
| Average True Range (ATR) | 0.15 | 1.81 |
| MACD | -0.00 | -0.32 |
| Stochastic Oscillator | 59.79 | 36.27 |
OPAL Fuels Inc is a fully integrated leader in the capture and conversion of biogas into low-carbon-intensity renewable natural gas and Renewable Power. The company is also engaged in the marketing and distribution of RNG to heavy-duty trucking and other hard-to-decarbonize industrial sectors. The company designs, develops, constructs, operates, and services Fueling Stations for trucking fleets across the country that use natural gas to displace diesel as their transportation fuel. The company derives revenue from the sale of Renewable Power, design, development, construction, and service of Fueling Stations, and sales of RNG produced by OPAL and third parties as pipeline-quality natural gas. The Company has three operating segments: RNG Fuel, Fuel Station Services, and Renewable Power.
Assembly Biosciences Inc is a clinical-stage biotechnology company. The Company's pipeline includes multiple clinical-stage investigational therapies, including: (1) two long-acting helicase-primase inhibitors (HPI) for the treatment of recurrent genital herpes; (2) an orally bioavailable hepatitis delta virus entry inhibitor; and (3) a potent next-generation capsid assembly modulator designed to disrupt the replication cycle of hepatitis B virus (HBV) at several key points. The Company's pipeline also includes a novel, oral broad-spectrum non-nucleoside polymerase inhibitor (NNPI) for the treatment of transplant-related herpesviruses.